Skip to main content

Table 1 Relationship Between Clinicopathological Features and PD-L1 Expression and Tumor-Infiltrating Lymphocytes in the Entire Cohort

From: Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas

  Total (N = 514) PD-L1 in tumor cells PD-L1 in immune cells
positive negative positive negative
Sex
 Male 347 (68%) 65 (19%) 282 (81%) 170 (49%) 177 (51%)
 Female 167 (32%) 36 (22%) 131 (78%) 74 (44%) 93 (56%)
Age, median (years, range) 65 (27–88) 66 (27–88) 64 (29–88) 66 (27–88) 64 (30–86)
Tumor site
 Lower 1/3 332 (65%) 63 (19%) 269 (81%) 156 (47%) 176 (53%)
 Middle 1/3 103 (20%) 17 (17%) 86 (83%) 50 (49%) 53 (51%)
 Upper 1/3 79 (15%) 21 (27%) 58 (73%) 38 (48%) 41 (52%)
Histologic type   * P = 0.008   * P < 0.001  
 Tubular adenocarcinoma 415 (81%) 87 (21%) 328 (79%) 214 (52%) 201 (48%)
 Poorly cohesive carcinoma 83 (16%) 10 (12%) 73 (88%) 22 (27%) 61 (73%)
 Mucinous carcinoma 9 (2%) 0 9 (100%) 2 (22%) 7 (78%)
 Undifferentiated carcinoma 7 (1%) 4 (57%) 3 (43%) 6 (86%) 1 (14%)
Lauren classification   * P = 0.023   * P = 0.019  
 Intestinal 286 (56%) 46 (16%) 240 (84%) 149 (52%) 137 (48%)
 Diffuse 228 (44%) 55 (24%) 173 (76%) 95 (42%) 133 (58%)
Lymphatic invasion   * P < 0.001    
 Present 230 (45%) 67 (29%) 163 (71%) 100 (43%) 130 (57%)
Depth of invasion (pT)   * P < 0.001   * P = 0.006  
 pT1 (mucosa, submucosa) 262 (51%) 29 (11%) 233 (89%) 137 (52%) 125 (48%)
 pT2 (muscularis proper) 46 (9%) 10 (22%) 36 (78%) 27 (59%) 19 (41%)
 pT3 (subserosa) 97 (19%) 25 (26%) 72 (74%) 42 (43%) 55 (57%)
 pT4 (serosa or beyond) 109 (21%) 37 (34%) 72 (66%) 38 (35%) 71 (65%)
Lymph node metastasis   * P = 0.008   * P = 0.004  
 Present 215 (42%) 54 (25%) 161 (75%) 86 (40%) 129 (60%)
Tumor stage (pTNM)   * P < 0.001   * P = 0.008  
 Stage I 277 (54%) 36 (13%) 241 (87%) 148 (53%) 129 (47%)
 Stage II 81 (16%) 23 (28%) 58 (72%) 39 (48%) 42 (52%)
 Stage III 130 (25%) 33 (25%) 97 (75%) 49 (38%) 81 (62%)
 Stage IV 26 (5%) 9 (35%) 17 (65%) 8 (31%) 18 (69%)
  Total (N = 514) CD8+ population FOXP3+ population PD-1+ population
  high low high low high low
Sex
 Male 347 (68%) 177 (51%) 170 (49%) 161 (46%) 186 (54%) 126 (36%) 221 (64%)
 Female 167 (32%) 80 (48%) 87 (52%) 79 (47%) 88 (53%) 55 (33%) 112 (67%)
Age, median (years, range) 65 (27–88) 65 (27–88) 65 (30–86) 66 (27–84) 63 (29–88) 67 (40–88) 63 (27–88)
Tumor site       * P = 0.049  
 Lower 1/3 332 (65%) 162 (49%) 170 (51%) 162 (49%) 170 (51%) 108 (33%) 224 (67%)
 Middle 1/3 103 (20%) 46 (45%) 57 (55%) 46 (45%) 57 (55%) 37 (36%) 66 (64%)
 Upper 1/3 79 (15%) 49 (62%) 30 (38%) 32 (41%) 47 (59%) 36 (46%) 43 (54%)
Histologic type     * P = 0.001    
 Tubular adenocarcinoma 415 (81%) 209 (50%) 206 (50%) 209 (50%) 206 (50%) 152 (37%) 263 (63%)
 Poorly cohesive carcinoma 83 (16%) 37 (45%) 46 (55%) 25 (30%) 58 (70%) 22 (27%) 61 (73%)
 Mucinous carcinoma 9 (2%) 4 (44%) 5 (56%) 3 (33%) 6 (67%) 1 (11%) 8 (89%)
 Undifferentiated carcinoma 7 (1%) 7 (100%) 0 3 (43%) 4 (57%) 6 (86%) 1 (14%)
Lauren classification   * P = 0.004   * P = 0.002    
 Intestinal 286 (56%) 127 (44%) 159 (56%) 151 (53%) 135 (47%) 97 (34%) 189 (66%)
 Diffuse 228 (44%) 130 (57%) 98 (43%) 89 (39%) 139 (61%) 84 (37%) 144 (63%)
Lymphatic invasion   * P = 0.033   * P = 0.017   * P = 0.041  
 Present 230 (45%) 127 (55%) 103 (45%) 94 (41%) 136 (59%) 92 (40%) 138 (60%)
Depth of invasion (pT)   * P = 0.006   * P < 0.001    
 pT1 (mucosa, submucosa) 262 (51%) 112 (43%) 150 (57%) 152 (58%) 110 (42%) 85 (32%) 177 (68%)
 pT2 (muscularis proper) 46 (9%) 31 (67%) 15 (33%) 22 (48%) 24 (52%) 20 (43%) 26 (57%)
 pT3 (subserosa) 97 (19%) 54 (56%) 43 (44%) 34 (35%) 63 (65%) 34 (35%) 63 (65%)
 pT4 (serosa or beyond) 109 (21%) 60 (55%) 49 (45%) 32 (29%) 77 (71%) 42 (39%) 67 (61%)
Lymph node metastasis     * P < 0.001    
 Present 215 (42%) 112 (52%) 103 (48%) 71 (33%) 144 (67%) 77 (36%) 138 (64%)
Tumor stage (pTNM)     * P < 0.001    
 Stage I 277 (54%) 126 (45%) 151 (55%) 163 (59%) 114 (41%) 95 (34%) 182 (66%)
 Stage II 81 (16%) 50 (62%) 31 (38%) 29 (36%) 52 (64%) 30 (37%) 51 (63%)
 Stage III 130 (25%) 66 (51%) 64 (49%) 39 (30%) 91 (70%) 44 (34%) 86 (66%)
 Stage IV 26 (5%) 15 (58%) 11 (42%) 9 (35%) 17 (65%) 12 (46%) 14 (54%)
  1. PD-L1 positive in tumor cells (n = 101); PD-L1 negative in tumor cells (n = 413); PD-L1 positive in immune cells (n = 244); PD-L1 negative in immune cells (n = 270)
  2. CD8+ high (n = 257), CD8+ low (n = 257); FOXP3+ high (n = 240); FOXP3+ low (n = 274), PD-1+ high (n = 181); PD-1+ low (n = 333)
  3. P values with statistically significant differences (< 0.05) are marked with an asterisk (*)